@article{08a703c95cec4277b52ec2d3ccf23bab,
title = "Cost-effectiveness: maximizing impact by meticulous data",
author = "Blommestein, {Hedwig M.} and Sonja Zweegman",
note = "Funding Information: Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute). Funding Information: Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute).",
year = "2022",
month = aug,
day = "11",
doi = "https://doi.org/10.1182/blood.2022016958",
language = "English",
volume = "140",
pages = "525--526",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",
}